| # | Drug | Count |
|---|---|---|
| 0 | LEVETIRACETAM | 32 |
| 1 | METHYLPREDNISOLONE | 32 |
| 2 | TACROLIMUS | 29 |
| 3 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 28 |
| 4 | TACROLIMUS OINTMENT 0.1% | 28 |
| 5 | NIVOLUMAB | 27 |
| 6 | LEVETIRACETAM IN SODIUM CHLORIDE | 25 |
| 7 | LEVETIRACETAM INJECTION | 25 |
| 8 | LEVETIRACETAM ORAL | 25 |
| 9 | MYCOPHENOLATE MOFETIL | 24 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PIMECROLIMUS | 9 | 0.0050 |
| 1 | ATRACURIUM BESYLATE | 2 | 0.0028 |
| 2 | FOSCARNET SODIUM | 8 | 0.0020 |
| 3 | FOSPHENYTOIN SODIUM | 4 | 0.0015 |
| 4 | SOYBEAN OIL | 1 | 0.0015 |
| 5 | DOCUSATE SODIUM 50 MG AND SENNOSIDES 8.6 MG | 1 | 0.0012 |
| 6 | FINGOLIMOD HYDROCHLORIDE | 4 | 0.0008 |
| 7 | CEFOTAXIME INJECTION | 3 | 0.0007 |
| 8 | COBIMETINIB | 3 | 0.0007 |
| 9 | PRALSETINIB | 1 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 56 |
| 1 | Platinum-based Drug [EPC] | 30 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 27 |
| 3 | Anti-epileptic Agent [EPC] | 26 |
| 4 | Mood Stabilizer [EPC] | 26 |
| 5 | Alkylating Drug [EPC] | 20 |
| 6 | Benzodiazepine [EPC] | 19 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 17 |
| 8 | Calcineurin Inhibitor Immunosuppressant [EPC] | 16 |
| 9 | Proton Pump Inhibitor [EPC] | 16 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Neuraminidase Inhibitor [EPC] | 1 | 0.0004 |
| 1 | Lipid Emulsion [EPC] | 1 | 0.0004 |
| 2 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 5 | 0.0004 |
| 3 | Nonergot Dopamine Agonist [EPC] | 5 | 0.0003 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 3 | 0.0003 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 27 | 0.0003 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 13 | 0.0003 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 5 | 0.0002 |
| 8 | Melatonin Receptor Agonist [EPC] | 3 | 0.0002 |
| 9 | Topoisomerase Inhibitor [EPC] | 16 | 0.0002 |